Filtered By:
Condition: Thrombocytopenia
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 914 results found since Jan 2013.
Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan
Int J Hematol. 2022 Sep 4. doi: 10.1007/s12185-022-03445-2. Online ahead of print.ABSTRACTGlobal vaccination against the coronavirus disease 2019 (COVID-19) is thought to be the most effective way to end or at least contain the COVID-19 pandemic. However, despite the good safety profiles and effectiveness of the available COVID-19 vaccines, rare but serious hematological complications have emerged, including thromboembolic outcomes with thrombocytopenia following the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and Ad26.COV.2.S (Johnson & Johnson/Janssen) vaccines. Moreover, COVID-19 vaccination may be linked to the developmen...
Source: International Journal of Hematology - September 4, 2022 Category: Hematology Authors: Chia-Yu Chen Tzu-Ting Chen Ching-Yun Hsieh Ming-Yu Lien Su-Peng Yeh Chi-Ching Chen Source Type: research
Semi-selective plasma filtration applied to the treatment of acquired thrombotic thrombocytopenic purpura following bnt162b2 administration
We report a case of a 63-year-old male who developed neurological symptoms after receiving the second dose of the bnt162b2 vaccine. Blood tests performed upon admission to the Emergency Department revealed severe thrombocytopenia and microangiopathic hemolytic anemia. ADAMTS13 activity was undetectable and antibody titer was high. Due to the rapid neurological deterioration, steroid therapy with prednisone was started at an initial dose of 1 mg/kg/day. Rituximab therapy was started to prevent the formation of new antibodies. Given the slow response to this therapy, we added Caplacizumab, (a monoclonal antibody anti-Von Wil...
Source: Journal of Nephrology - September 3, 2022 Category: Urology & Nephrology Authors: Roberta Fenoglio Martina Marchisio Alessandra Baffa Giacomo Quattrocchio Dario Roccatello Source Type: research
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review
In conclusion, there may be an association between COVID-19 vaccination and autoimmune and inflammatory diseases. Some ADs seem to be more common than others. Vaccines and SARS-CoV-2 may induce autoimmunity through similar mechanisms. Large, well-controlled studies are warranted to validate this relationship and assess additional variables such as genetic and other environmental factors.PMID:36041291 | PMC:PMC9399140 | DOI:10.1016/j.jaut.2022.102898
Source: Journal of Autoimmunity - August 30, 2022 Category: Allergy & Immunology Authors: Yhojan Rodr íguez Manuel Rojas Santiago Beltr án Fernando Polo Laura Camacho-Dom ínguez Samuel David Morales M Eric Gershwin Juan-Manuel Anaya Source Type: research
Quantitative Interpretation of PF4/Heparin-EIA Optical Densities in Predicting for Platelet-Activating VITT Antibodies
CONCLUSIONS: VITT serology resembles HIT in that greater EIA OD reactivity predicts for higher probability of positive testing for platelet-activating antibodies. Unlike the situation with HIT antibodies, however, diluting putative VITT serum increases probability of a positive platelet activation assay, suggesting that optimal complex formation depends on the stoichiometric ratio of PF4 and anti-PF4 VITT antibodies.PMID:36006172 | DOI:10.1111/jth.15862
Source: Thrombosis and Haemostasis - August 25, 2022 Category: Hematology Authors: Linda Sch önborn Thomas Thiele Max Esefeld Khalil El Debuch Jan Wesche Sabrina E Seck Lars Kaderali Martina Wolff Theodore E Warkentin Andreas Greinacher Source Type: research
Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations
CONCLUSIONS: The reporting rate of 'typical'/'possible' TTS post first-dose vaccination in this dataset is 7.5 per million vaccinated persons; few cases were reported after subsequent doses, including booster doses. Peak reporting coincided with media-driven attention. Medical history differences versus a reference population indicate potentially unidentified risk factors. The decreasing fatality rate correlates with increasing awareness and publication of diagnostic/treatment guidelines. Adjudication was hindered by unreported parameters, and an algorithm was developed to classify potential TTS cases; comprehensive report...
Source: Vaccine - August 21, 2022 Category: Allergy & Immunology Authors: Michael A Laffan Sue Rees Madhavi Yadavalli Lisa Beth Ferstenberg Nirmal Kumar Shankar Jennie Medin Nadia Foskett Matthew Arnold Hugo Gomes da Silva Prakash Bhuyan Magnus Nord Source Type: research
Potential mechanisms of vaccine-induced thrombosis
Eur J Intern Med. 2022 Aug 8:S0953-6205(22)00274-6. doi: 10.1016/j.ejim.2022.08.002. Online ahead of print.ABSTRACTVaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare syndrome characterized by high-titer anti-platelet factor 4 (PF4) antibodies, thrombocytopenia and arterial and venous thrombosis in unusual sites, as cerebral venous sinuses and splanchnic veins. VITT has been described to occur almost exclusively after administration of ChAdOx1 nCoV-19 and Ad26.COV2.S adenovirus vector- based COVID-19 vaccines. Clinical and laboratory features of VITT resemble those of heparin-induced thrombocytopenia (H...
Source: European Journal of Internal Medicine - August 11, 2022 Category: Internal Medicine Authors: Marco Marietta Valeria Coluccio Mario Luppi Source Type: research
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
Therapie. 2022 Jul 13:S0040-5957(22)00120-2. doi: 10.1016/j.therap.2022.07.003. Online ahead of print.ABSTRACTThe deficiently designed and conducted initial clinical development plan and the occurrence of thrombotic thrombocytopenia cases, have marked the 12-month journey of the AstraZeneca coronavirus disease 2019 (COVID-19) vaccine after it was first administered to humans. When it was authorized, there were no available efficacy data in the elderly. However, this age group was included in the product labelling based on immunogenicity data. The lack of safety and efficacy data in the elderly that was acknowledged in the ...
Source: Therapie - July 30, 2022 Category: Psychiatry & Psychology Authors: Rafael Dal-R é Source Type: research
Overview of the immunological mechanism underlying severe fever with thrombocytopenia syndrome (Review)
Int J Mol Med. 2022 Sep;50(3):118. doi: 10.3892/ijmm.2022.5174. Epub 2022 Jul 20.ABSTRACTSevere fever with thrombocytopenia syndrome (SFTS) has been acknowledged as an emerging infectious disease that is caused by the SFTS virus (SFTSV). The main clinical features of SFTS on presentation include fever, thrombocytopenia, leukocytopenia and gastrointestinal symptoms. The mortality rate is estimated to range between 5‑30% in East Asia. However, SFTSV infection is increasing on an annual basis globally and is becoming a public health problem. The transmission cycle of SFTSV remains poorly understood, which is compounded by t...
Source: International Journal of Molecular Medicine - July 20, 2022 Category: Molecular Biology Authors: Tao Yang Huaying Huang Longfeng Jiang Jun Li Source Type: research
